C-reactive protein at discharge, diabetes mellitus and ≥1 hospitalization during previous year predict early readmission in patients with acute exacerbation of chronic obstructive pulmonary disease

COPD: Journal of Chronic Obstructive Pulmonary Disease

Volumn 12, Issue 3, 2015, Pages 311-320

  Crisafulli, Ernesto ^a   Torres, Antoni ^b   Huerta, Arturo ^b   Mendez, Raul ^c   Guerrero, Monica ^b   Martinez, Raquel ^c   Liapikou, Adamantia ^d   Soler, Nestor ^b   Sethi, Sanjay ^e   Menendez, Rosario ^c  

^a CARLO POMA HOSPITAL   (Italy)

^b UNIVERSITY OF BARCELONA   (Spain)

^c HOSPITAL UNIVERSITARIO LA FE   (Spain)

^d SOTIRIA GENERAL HOSPITAL   (Greece)

^e UNIVERSITY AT BUFFALO   (United States)

Author keywords

Acute exacerbation; Chronic obstructive pulmonary disease; Inflammatory response; Predictors; Readmission

Indexed keywords

ANTIBIOTIC AGENT; BIOLOGICAL MARKER; BUDESONIDE; C REACTIVE PROTEIN; CARBAPENEM DERIVATIVE; CEPHALOSPORIN DERIVATIVE; FLUTICASONE; FORMOTEROL; IPRATROPIUM BROMIDE; MACROLIDE; PENICILLIN DERIVATIVE; QUINOLONE DERIVATIVE; SALBUTAMOL; SALMETEROL; TERBUTALINE; THEOPHYLLINE; TIOTROPIUM BROMIDE;

ACUTE EXACERBATION OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE; ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; BLOOD CHEMISTRY; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DIABETES MELLITUS; DIABETIC PATIENT; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE EXACERBATION; DISEASE SEVERITY; FEMALE; HOSPITAL DISCHARGE; HOSPITAL PATIENT; HOSPITAL READMISSION; HOSPITALIZATION; HUMAN; INFLAMMATION; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MICROBIOLOGICAL EXAMINATION; MIDDLE AGED; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; OBSERVATIONAL STUDY; PREDICTIVE VALUE; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; RISK FACTOR; SENSITIVITY AND SPECIFICITY; SERUM; UNIVERSITY HOSPITAL; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SPAIN; STATISTICS AND NUMERICAL DATA;

AGED; C-REACTIVE PROTEIN; DIABETES MELLITUS; FEMALE; HOSPITALIZATION; HUMANS; MALE; MULTIVARIATE ANALYSIS; PATIENT READMISSION; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RISK FACTORS; SPAIN;

EID: 84933531098     PISSN: 15412555     EISSN: 15412563     Source Type: Journal    
DOI: 10.3109/15412555.2014.933954     Document Type: Article

References (39)

1. Buist AS, McBurnie MA, Vollmer WM, et al. on behalf of BOLD Collaborative Research Group: International variation in the prevalence of COPD (the BOLD Study): a populationbased prevalence study. Lancet 2007; 370:741-750.
2. Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med 2006; 3:e442.
3. Donaldson GC, Seemungal TA, Bhowmik A, Wedzicha JA. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 2002; 57:847-852.
4. Donaldson GC, Wilkinson TMA, Hurst JR, et al. Exacerbations and time spent outdoors in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005; 171:446-452.
5. Seemungal TA, Donaldson GC, Paul EA, et al. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998; 157:1418-1422.
6. Soler-Catalunã JJ, Martínez-Garciá MA, Román Sánchez P, et al. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax 2005; 60:925-931.
7. Hurst JR, Vestbo J, Anzueto A, et al on behalf of Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) Investigators. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med 2010; 363:1128-1138.
8. Hurst JR, Donaldson GC, Quint JK, et al. Temporal clustering of exacerbations in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2009; 179(5):369-74.
9. Baker CL, Zou KH, Su J. Risk assessment of readmissions following an initial COPD-related hospitalization. Int J Chron Obstruct Pulmon Dis 2013; 8:551-559.
10. Nantsupawat T, Limsuwat C, Nugent K. Factors affecting chronic obstructive pulmonary disease early rehospitalization. Chron Respir Dis 2012; 9(2):93-98.
11. Strassels SA, Smith DH, Sullivan SD, Mahajan PS. The cost of treating COPD in the United States. Chest 2001; 119:344-352.
12. FitzGerald JM, Haddon JM, Bradly-Kennedy C, et al. Resource use study in COPD (RUSIC): a prospective study to quantify the Effects of COPD exacerbations on health care resource use among COPD patients. Can Respir J 2007; 14:145-152.
13. Elixhauser A, Au DH, Podulka J. Readmissions for Chronic Obstructive Pulmonary Disease, 2008: Statistical Brief #121. Healthcare Cost and Utilization Project (HCUP) Statistical Briefs (Internet). Rockville, MD: Agency for Health Care Policy and Research; 2006-2011.
14. Garcia-Aymerich J, Farrero E, Félez MA, et al. on behalf of Estudi del Factors de Risc d'Agudització de la MPOC investigators. Risk factors of readmission to hospital for a COPD exacerbation: a prospective study. Thorax 2003; 58:100-105.
15. Gudmundsson G, Gislason T, Janson C, et al. Risk factors for rehospitalisation in COPD: role of health status, anxiety and depression. Eur Respir J 2005; 26:414-419.
16. Almagro P, Cabrera FJ, Diez J, et al. on behalf of Working Group on COPD, Spanish Society of Internal Medicine. Comorbidities and short-term prognosis in patients hospitalized for acute exacerbation of COPD: the EPOC en Servicios de medicina interna (ESMI) study. Chest 2012; 142:1126-1133.
17. Steer J, Norman EM, Afolabi OA, et al. Dyspnoea severity and pneumonia as predictors of in-hospital mortality and early readmission in acute exacerbations of COPD. Thorax 2012; 67:117-121.
18. González C, Servera E, Marín J. Importance of noninvasively measured respiratory muscle overload among the causes of hospital readmission of COPD patients. Chest 2008; 133:941-947.
19. Almagro P, Barreiro B, Ochoa de Echaguen A, et al. Risk factors for hospital readmission in patients with chronic obstructive pulmonary disease. Respiration 2006; 73:311-317.
20. Vilaró J, Ramirez-Sarmiento A, Martínez-Llorens JM et al. Global muscle dysfunction as a risk factor of readmission to hospital due to COPD exacerbations. Respir Med 2010; 104:1896-1902.
21. Coventry PA, Gemmell I, Todd CJ. Psychosocial risk factors for hospital readmission in COPD patients on early discharge services: a cohort study. BMC Pulm Med 2011; 11:49.
22. de Batlle J, Mendez M, Romieu I, et al. on behalf of PACCOPD Study Group. Cured meat consumption increases risk of readmission in COPD patients. Eur Respir J 2012; 40:555-560.
23. McGhan R, Radcliff T, Fish R, et al. Predictors of rehospitalization and death after a severe exacerbation of COPD. Chest 2007; 132:1748-1755.
24. Wong AW, Gan WQ, Burns J, et al. Acute exacerbation of chronic obstructive pulmonary disease: infl uence of social factors in determining length of hospital stay and readmission rates. Can Respir J 2008; 15:361-364.
25. Cao Z, Ong KC, Eng P, et al. Frequent hospital readmissions for acute exacerbation of COPD and their associated factors. Respirology 2006; 11:188-195.
26. Bhatt SP, Khandelwal P, Nanda S, et al. Serum magnesium is an independent predictor of frequent readmissions due to acute exacerbation of chronic obstructive pulmonary disease. Respir Med 2008; 102:999-1003.
27. Vestbo J, Hurd SS, Agustí AG, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2013; 187:347-365.
28. Anthonisen NR, Manfreda J, Warren CP, et al. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 1987; 106:196-204.
29. Rana JS, Mittleman MA, Sheikh J, et al. Chronic obstructive pulmonary disease, asthma, and risk of type 2 diabetes in women. Diabetes Care 2004; 27:2478-2484.
30. Spranger J, Kroke A, Möhlig M, et al. Infl ammatory cytokines and the risk to develop type 2 diabetes: results of the prospective population-based European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study. Diabetes 2003; 52:812-817.
31. Yeh HC , Punjabi NM , Wang NY, et al. Cross-sectional and prospective study of lung function in adults with type 2 diabetes: the Atherosclerosis Risk in Communities (ARIC) study. Diabetes Care 2008; 31:741-746.
32. Isotani H, Nakamura Y, Kameoka K, et al. Pulmonary diff using capacity, serum angiotensin-converting enzyme activity and the angiotensin-converting enzyme gene in Japanese noninsulin-dependent diabetes mellitus patients. Diabetes Res Clin Pract 1999; 43:173-177.
33. Schäcke H, Döcke WD, Asadullah K. Mechanisms involved in the side Effects of glucocorticoids. Pharmacol Ther 2002; 96(1):23-43.
34. Perera WR, Hurst JR, Wilkinson TM, et al. Infl ammatory changes, recovery and recurrence at COPD exacerbation. Eur Respir J 2007; 29:527-534.
35. Sethi S, Wrona C, Eschberger K, et al. Infl ammatory profi le of new bacterial strain exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2008; 177(5):491-497.
36. Gan WQ, Man SF, Senthilselvan A, Sin DD. Association between chronic obstructive pulmonary disease and systemic infl ammation: a systematic review and a meta-analysis. Thorax 2004; 59(7):574-580.
37. Dahl M, Vestbo J, Lange P, et al. C-reactive protein as a predictor of prognosis in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007; 175(3):250-5.
38. Agustí A, Edwards LD, Rennard SI, et al. on behalf of Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) Investigators. Persistent systemic infl ammation is associated with poor clinical outcomes in COPD: a novel phenotype. PLoS One 2012; 7(5):e37483.
39. Thomsen M, Ingebrigtsen TS, Marott JL, et al. Infl ammatory biomarkers and exacerbations in chronic obstructive pulmonary disease. JAMA 2013; 309:2353-2361.